# Mirum Pharmaceuticals, Inc. (MIRM): A Promising Biotech Play with a 12.88% Upside Potential

- Link: https://www.directorstalkinterviews.com/mirum-pharmaceuticals-inc-mirm-a-promising-biotech-play-with-a-12-88-upside-potential/4121236894
- Published: 2026-01-27T11:16:48+00:00
- Author: Madison Wilson

For investors keeping a close watch on the biotechnology sector, Mirum Pharmaceuticals,
Inc. (NASDAQ: MIRM) presents a compelling opportunity. With a robust market capitalization
of $5.01 billion, this U.S.-based biopharmaceutical company is focused on the development
and commercialization of novel therapies for rare and orphan diseases, positioning
itself uniquely within the healthcare landscape.

Mirum’s flagship product, LIVMARLI (maralixibat), is an orally administered inhibitor
approved for treating cholestatic pruritus in Alagille syndrome patients. This product
is indicative of Mirum’s focus on niche markets with significant unmet medical needs.
The company is also actively commercializing Cholbam and Chenodal, expanding its
influence and reach within the bile acid disorder treatment domain. Additionally,
Mirum is advancing Volixibat through Phase 2b trials, targeting cholestatic liver
diseases, which could potentially broaden its therapeutic portfolio.

Currently, Mirum’s stock is trading at $96.92, reaching the upper spectrum of its
52-week range of $38.39 to $96.92. This price is supported by strong momentum, with
the 50-day and 200-day moving averages at $77.00 and $62.87, respectively, reflecting
a solid upward trajectory. The Relative Strength Index (RSI) at 59.68 and a MACD
significantly above the signal line suggest that the stock is neither overbought
nor oversold, indicating stability in its current valuation.

Despite the absence of conventional valuation metrics such as P/E or PEG ratios—
often challenging in biotech firms focused heavily on R&D—Mirum boasts a remarkable
revenue growth rate of 47.20%. However, like many in the biotech space, Mirum is
yet to achieve profitability, highlighted by its EPS of -0.84 and a negative return
on equity of -15.81%. The forward P/E ratio stands at -476.66, reflecting anticipated
continued investments in research and development as the company aims for future
growth and breakthroughs.

From a cash flow perspective, Mirum is in a favorable position, generating a free
cash flow of $48.7 million. This financial cushion provides the company with the
flexibility to fund its ongoing clinical trials and product development efforts,
essential for long-term success in the competitive biotech industry.

Analysts are overwhelmingly bullish on Mirum’s prospects, with 10 buy ratings and
no hold or sell recommendations. The average target price of $109.40 suggests a 
potential upside of 12.88% from its current trading level, with target prices ranging
from $95.00 to $140.00. This optimism is fueled by Mirum’s strategic focus on rare
diseases, a segment expected to see significant growth as medical advancements continue
to unlock new treatment possibilities.

While Mirum does not currently offer a dividend, its zero payout ratio indicates
that the company is reinvesting earnings back into its growth initiatives, a common
strategy for growth-oriented biotech firms. This reinvestment is critical as Mirum
seeks to expand its product pipeline and enhance its market presence.

In summary, Mirum Pharmaceuticals offers a promising investment avenue for those
looking to capitalize on the burgeoning biotech sector, particularly within the 
niche of rare and orphan diseases. Its innovative drug portfolio, strong revenue
growth, and favorable analyst outlook make it a stock worth considering for investors
seeking potential upside and long-term value in a dynamic industry.

Share on:
